Anti-amyloid antibody treatments for Alzheimer's disease
- PMID: 37697714
- PMCID: PMC11235913
- DOI: 10.1111/ene.16049
Anti-amyloid antibody treatments for Alzheimer's disease
Abstract
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease directed against amyloid-β. This is a joint statement of the European Association of Neurology and the European Psychiatric Association. After numerous unsuccessful endeavors to create a disease-modifying therapy for Alzheimer's disease, substantial and consistent evidence supporting the clinical effectiveness of monoclonal antibodies aimed at amyloid-β is finally emerging. The latest trials not only achieved their primary objective of slowing the progression of the disease over several months but also demonstrated positive secondary clinical outcomes and a decrease in amyloid-β levels as observed through positron emission tomography scans. Taken as a whole, these findings mark a significant breakthrough by substantiating that reducing amyloid-β yields tangible clinical benefits, beyond mere changes in biomarkers. Concurrently, the regular utilization of the new generation of drugs will determine whether statistical efficacy translates into clinically meaningful improvements. This may well signify the dawning of a new era in the development of drugs for Alzheimer's disease.
Keywords: anti-amyloid immunisation; fluid and imaging biomarkers; mild cognitive impairment and dementia; monoclonal antibodies; treatment of cognitive decline.
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Conflict of interest statement
R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen‐Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk; and was principal investigator on the aducanumab phase 3 trials. P.F. has received research support/honoraria for lectures or advisory activities from Boehringer‐Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter.
Figures
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical